{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-001106","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.630468+00:00","generated_at":"2026-05-28T01:41:43.299007+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TG Therapeutics Prelim. Q4 BRIUMVI Rev $103.6M; FY2025 US Revenue Target $525M","bullets":["Preliminary Q4 2024 BRIUMVI U.S. net product revenue $103.6M; full year 2024 $310M.","FY2025 target total global revenue ~$540M, including BRIUMVI U.S. net product revenue ~$525M; target opex ~$300M.","2025 milestones: commence pivotal program for subcutaneous BRIUMVI; evaluate 30-min infusion; enroll in autoimmune trials.","Year-end 2024 cash position approx. $310M.","CEO states 2024 revenue far exceeded initial expectations; BRIUMVI well positioned for continued growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-001106","json":"https://secwatch.observer/filing/0001437749-25-001106.json","markdown":"https://secwatch.observer/filing/0001437749-25-001106.md","text":"https://secwatch.observer/filing/0001437749-25-001106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774925001106/0001437749-25-001106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774925001106/tgtx20250114_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:41:43.299007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}